Ensysce Biosciences
ENSC
11 hedge funds and large institutions have $253K invested in Ensysce Biosciences in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
10% more funds holding
Funds holding: 10 → 11 (+1)
7% more capital invested
Capital invested by funds: $237K → $253K (+$16.5K)
0.2% less ownership
Funds ownership: 0.63% → 0.44% (-0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$52.5K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$50.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.9K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$8.04K |
| 5 |
VF
Virtu Financial
New York
|
+$6.89K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9.96K |
| 2 |
Renaissance Technologies
New York
|
-$8K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$20 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $159K | +$50.9K | +5,587 | +36% |
|
|
2
Citadel Advisors
Miami,
Florida
| $43.7K | +$52.5K | +5,756 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $23.3K | +$16.9K | +1,852 | +152% |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $9.21K | – | – | – |
|
|
XT
5
XTX Topco
George Town,
Cayman Islands
| $6.7K | +$8.04K | +882 | New |
|
|
VF
6
Virtu Financial
New York
| $6K | +$6.89K | +756 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $4.19K | +$55 | +6 | +1% |
|
8
BlackRock
New York
| $494 | – | – | – |
|
|
MSG
9
Main Street Group
Glen Allen,
Virginia
| $185 | – | – | – |
|
10
Bank of America
Charlotte,
North Carolina
| $31 | +$36 | +4 | New |
|
|
PMFA
11
Plante Moran Financial Advisors
Southfield,
Michigan
| $10 | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$9.96K | -841 | Closed |
|
|
13
Renaissance Technologies
New York
| – | -$8K | -704 | Closed |
|
|
14
Wells Fargo
San Francisco,
California
| – | -$20 | -2 | Closed |
|
ENSC Hedge Fund Activity: Q2 2024 in Review
11 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q2 2024, worth a combined $253K — up 7% from $237K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ENSC positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $52.5K. The largest seller was UBS Group, exiting entirely with an estimated $9.96K sold.
- 11 institutional investors held Ensysce Biosciences (ENSC) as of Q2 2024, up from 10 in Q1 2024.
- Funds reported $253K of Ensysce Biosciences stock for Q2 2024, up 7% quarter-over-quarter.
- 4 funds opened new Ensysce Biosciences positions in Q2 2024 and 3 closed out, a net change of +1 holder.
- The largest Ensysce Biosciences buyer in Q2 2024 was Citadel Advisors, an estimated $52.5K added.
- The largest Ensysce Biosciences seller in Q2 2024 was UBS Group, an estimated $9.96K sold.
Based on aggregated 13F filings for Q2 2024.